ReviewFrontiers in psychiatry2026
Decreased hippocampal neurogenesis and post-stroke depression.
Review in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unraveling the Mechanistic Insights ofNutrients · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-stroke depression (PSD) is a common and serious complication following stroke, affecting approximately one-third of survivors and contributing to poor functional recovery. Its pathophysiology is multifactorial, with recent evidence highlighting decreased hippocampal neurogenesis as a key mechanistic contributor. This review aims to examine the specific role of hippocampal neurogenesis in PSD, focusing on (1) the evidence linking impaired neurogenesis to PSD onset (2), the underlying molecular and cellular mechanisms-including dysregulation of the hypothalamic-pituitary-adrenal(HPA) axis, neuroinflammation, altered neurotrophic signaling, and neurotransmitter disturbances-and (3) current and emerging therapeutic strategies that promote neurogenesis for PSD management. Pharmacological agents (e.g., antidepressants), neuroregulatory interventions, and lifestyle-based approaches show promise in restoring neurogenic activity and alleviating depressive symptoms. In conclusion, impaired hippocampal neurogenesis represents a central pathway in PSD pathogenesis, offering a valuable target for future research and therapeutic development. Further studies are needed to fully elucidate these mechanisms and translate neurogenesis-focused treatments into clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.